BioSpace News Archive

FDA’s highest priorities is advancing policies that increase competition as a way to help make drugs more affordable and improve access.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company’s oral, small molecule, complement C5 inhibitor program and data from the Company’s global, Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) will be presented at the 23rd Congress of the European Hematology Association (EHA) from June 14-17, 2018 in Stockholm, Sweden.

X4 Pharmaceuticals will present clinical data highlighting their Phase II X4P-001-RD drug.

Griffin-American Healthcare REIT III, Inc. today announced operating results for the company’s first quarter ended March 31, 2018.

Innovative, Cochlear Implant Effortless Processor Provides Up To 18 Hours of Battery Life

Patients should not need to wait four months for these life-saving therapies

Shineco, Inc. (“Shineco” or the “Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today its financial results for the third quarter ended March 31, 2018.

- Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2018.